Eton Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Eton gains a new product candidate with up to $33.5 million in potential milestone payments if FDA approves and sales grow.
Leadership change shows internal promotion of experienced executive earning $520,800 annually with bonus potential.
Company seeks to treat more patients with existing drug, potentially expanding revenue sources.
Jenn Adams and Charles Casamento selected as directors; Grant Thornton confirmed as auditor for accountability oversight.
Eton pays $4.25 million fixed fees plus royalties to sell leishmaniasis treatment; 2025 market was $8.1 million annually.
Quarterly earnings announcement lets investors see revenue, costs, and company health for January through March.
Management uses this adjusted earnings measure to help investors compare performance across periods consistently.
Stocky reads Eton Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Eton Pharmaceuticals, Inc.'s most recent tracked filing was a 8-K on 5 Aug 2026: Licensed rare disease drug ASN-001 from Auson Pharmaceuticals.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.